August 2018

New Indications

Denosumab (rch) (Prolia) is now indicated to increase bone mass in women and men at increased risk of fracture due to long-term systemic glucocorticoid therapy.

Ixekizumab (rch) (Taltz) is now indicated for the treatment of active psoriatic arthritis in adults who have responded inadequately, or who are intolerant, to previous DMARD therapy. Taltz may be used as monotherapy or in combination with a conventional DMARD (e.g. methotrexate).

Nepafenac (Ilevro) is now indicated for the reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non-proliferative diabetic retinopathy.

Pembrolizumab (Keytruda) in combination with pemetrexed and platinum chemotherapy is now indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC).

Trametinib (Mekinist) in combination with dabrafenib is now indicated for the adjuvant treatment of melanoma with a BRAF V600 mutation and involvement of the lymph node(s), following complete resection.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au